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Despite their lower threshold for
moving brood, low-temperature-
incubated ants selected warmer
parts of their artificial nest for brood
placement. Weidenmu¨ller et al. [3]
speculate that this behaviour relates to
the best strategies for incubating brood
in spring and summer. They suggest
that in spring, heat is a limiting
resource. Thus, colonies place brood
in the warmest part of the nest, but
stand ready to move it away rapidly
should the temperature become
super-optimal. In summer, heat is
the enemy, and it is probably best if
brood is kept in parts of the nest
where high temperatures are never
experienced, thus saving the labour
of frequently moving brood around,
and reducing the risk that it will ever
experience lethal temperatures.
Hence, a rapid response to rising
temperature is not required, for the
brood is located in a cool part
of the nest. This argument is a bit
counter-intuitive, and I am not
entirely convinced by it; however,
the speculation is supported by the
fact that high-temperature-reared
workers moved brood to
cooler parts of the artificial nest
than low-temperature-reared
workers.
Finally, Weidenmu¨ller et al. [3]
found that adult ants that were
exposed to increasing temperatures
repeatedly developed lower task
thresholds and thus started to move
pupae at lower temperatures than
they had done previously. This
supports the idea that task threshold
can be reinforced by experience [7],
increasing the variance in task
thresholds among workers in
a colony. Interestingly, although
experience decreased the threshold
for carrying out brood, it did not
change the threshold for the first
response; that is, picking the brood
up. This suggests that experienced
workers do not become more
sensitive to increasing temperature,
but become more efficient in their
response to it.
The Weidenmu¨ller et al. [3] study
is important because it demonstrates
another way by which non-genetic
mechanisms can result in significant
inter-individual behaviour within
colonies of insects. The work focussed
on brood incubation behaviour, but
it is not unreasonable to suspect
that thresholds of other behaviours
could also be affected by a worker’s
experience as a pupa or larva. For
example, in the honey bee, larval diet
has a profound effect on morphology,
and likely the behaviour of the
subsequent adults [8]. Thus, larval
feeding, pupal incubation, age and
genetics may all interact to produce
workers with different task thresholds,
and thus colonies that are more
homeostatic and efficient.
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The small GTP-binding protein Arf6 is known to be an important regulator of the
actin cytoskeleton and of cell motility associated with metastasis. A recent
study identifies yet another role for Arf6 in metastasis — as a regulator of
plasma-membrane-derived microvesicle release.Richard T. Premont*
and Robert Schmalzigaug
Perhaps the most perilous moment in
carcinogenesis is when transformed
cells break free from their original
microenvironment, seeking to flourish
elsewhere. As tumor cellsmigrate away
from their site of origin, they can elude
the remaining normal spatial controls
that might have kept the tumor from
expanding explosively and can go on
to find new environments where they
can thrive, forming new and often
more aggressive tumors.Established anti-cancer therapies
target cell proliferation, as transformed
cells divide relentlessly in the absence
of feedback controls that normally limit
the growth of non-transformed cells.
An alternative therapeutic approach
would be to prevent tumor cells from
migrating away from their site of origin;
much effort has therefore been
expended in developing a molecular
understanding of cell migration in
normal and tumor cells. The Arf6
protein is one important mediator of
tumor-cell migration and invasiveness
during metastasis, suggesting thatArf6-regulated pathways may provide
valuable targets for therapeutic
intervention to reduce metastatic
potential.
Arf6 is a member of the
ADP-ribosylation factor (Arf) family of
small GTP-binding proteins [1]. Like
all GTP-binding regulatory proteins,
Arf6 cycles between an inactive
GDP-bound form and an active
GTP-bound form. Activity is controlled
by guanine nucleotide exchange
factors (GEFs) that promote GDP
release and GTP binding, and
GTPase-activating proteins (GAPs)
that promote hydrolysis of bound GTP
to GDP [1]. Unlike other Arf family
members, which function primarily
to coordinate intracellular vesicle
trafficking events in the Golgi and
endoplasmic reticulum, Arf6 functions
primarily at the plasma membrane [1].
The traditional view of Arf6 is that it
Dispatch
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trafficking, but that it specifically
regulates traffic to and from the
plasma membrane [1]. As such, Arf6
is an important regulator of cellular
signaling by affecting the ability of
receptor proteins to make their way
to and from the cell surface. Arf6 also
has an important role in coordinating
cell shape and motility by regulating
the actin cytoskeleton, especially
in tandem with the Rho-family
member Rac1 [2–4]. Arf6 functions
as a signaling intermediate, linking
cell-surface receptors to the
activation of several enzymes
involved in plasma membrane lipid
metabolism and lipid-messenger
generation [1]. Given the diversity
and complexity of Arf6 functions,
and the apparently limited capacity
of other Arf isoforms to perform these
specific tasks, it is not surprising
then that mice lacking Arf6 die
during embryogenesis [5].
Arf6-regulated pathways have
been studied extensively in the context
of cancer, especially in tumor-cell
metastasis. In previous work, Sabe
and co-workers [6,7] explored
Arf6-dependent migration and invasion
in breast cancer-derived cell lines.
Breast tumor cells with a highly
invasive phenotype had increased
expression of Arf6 compared with less
invasive cells [8], and siRNA-mediated
knockdown of Arf6 expression reduced
cell migration and invasiveness [6].
Active Arf6 promoted the formation of
tumor cell invadopodia — membrane
protrusions that project into and digest
the extracellular matrix [6]. Arf6
localized to invadopodia, and an
inactive Arf6 mutant prevented
invadopodia formation and matrix
digestion [9]. In a series of recent
studies (reviewed in [7]), Sabe and
co-workers delineated a pathway
promoting metastatic potential in
breast cancer cells that began with
stimulation of the EGF receptor, to
activation of the Arf GEF GEP100/
BRAG2, of Arf6, and of the ArfGAP
protein ASAP1/AMAP1, which acts
as an Arf6 effector to recruit paxillin
and cortactin to invadopodia.
D’Souza-Schorey and colleagues [9,10]
performed similar studies with the LOX
invasive melanoma cell line. LOX
melanoma cells stably expressing
mutant forms of Arf6 that were either
locked in the active, GTP-bound state
or the inactive, GDP-bound state were







































Figure 1. Arf6 signaling pathways in the regulation of tumor-cell migration and metastasis.
In the well-known mitogen-activated protein kinase pathway, the EGF-bound EGF receptor
recruits the Ras GEF Sos to activate the small GTP-binding protein Ras, which initiates the
Raf–MEK–Erk kinase effector cascade to increase cell proliferation. Arf6 is similarly activated
downstream of extracellular receptors, such as the EGF receptor as shown here, as well as by
intracellular signals that activate Arf GEF proteins such as ARNO or GEP100. For many Arf6
pathways, the specific GEF remains to be identified (shown as ‘ArfGEF?’). Activated Arf6 binds
to effector proteins (such as phospholipase D (PLD), and the Rac1 GEFs Dock180 and kalirin),
some of which also function as regulatory ArfGAPs (ASAP1, ASAP3). These effectors initiate
further signaling pathways, through Rac1 or Erk, that promote further cellular events, or
may directly recruit proteins that alter cellular function (such as paxillin and cortactin in
invadopodia).(expressing only endogenous Arf6)
in a xenograft model using athymic
nude mice [10]. Mice injected
subcutaneously with LOXARF6-GTP cells
developed primary tumors that were
much smaller and grew more slowly
than those in mice injected with LOX
cells or LOXARF6-GDP cells [10].
However, despite this slower growth,
LOXARF6-GTP cells were much more
invasive of immediate surrounding
tissue. Nevertheless, in a direct
metastasis establishment assay, in
which tumor cells are injected into the
tail vein, LOXARF6-GDP cells showed
a small reduction in the number and
size of lung metastases compared with
LOX cells, whereas LOXARF6-GTP cells
failed to induce lungmetastases. These
findings indicate that Arf6 functions in
controlling both cell proliferation and
cell migration ability during metastasis.
In glioma cells, Arf6 has been shown
to promote invasion through activation
of Rac1 [11] and also to mediate
EGF-stimulated proliferation [12]. Invarious other cell types, the Arf GEFs
ARNO/cytohesin-2 and EFA6 [13]
have been implicated in promoting
cell migration, as have Arf GAPs, such
as ASAP3 [14] and GIT1/GIT2 [15].
In this issue of Current Biology,
D’Souza-Schorey and colleagues
[16] describe a mechanism whereby
activated Arf6 contributes to matrix
degradation during tumor cell invasion.
Surprisingly, they provide evidence for
Arf6-mediated regulation of an entirely
unexpected class of membrane
trafficking events: the release of
plasma membrane-derived
microparticles (Figure 1). These
tumor cell-derived microparticles
appear to derive from regions of the
plasma membrane that are distinct
from traditional invadosomes, but,
like invadosomes, these microparticles
are associated with matrix-digesting
proteases.
Microparticles are one of a class of
membranous structures released from
cells. Another such structure, the
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R1038exosome, is a lipid-delimited vesicle
released by the fusion of an intracellular
multivesicular body with the plasma
membrane, spewing the contained
vesicles into the extracellular milieu
[17]. Microparticles, in contrast, are
derived from outward budding and
fission from the plasma membrane
directly, the inverse of the well-known
inward vesiculation of clathrin-coated
pits [17]. These microparticles contain
integral membrane proteins derived
from their cells of origin and may also
carry cargo of select intracellular
proteins. Once thought to be the
product only of dying cells,
microparticles are now appreciated
also to be products of living
cells — both normal and, most
often, transformed [17]. Released
microparticles can find their way
even to the bloodstream, where they
can be used as markers of the cells
that released them. However, the
mechanisms regulating microvesicle
production by cells have remained
obscure.
In this new study, the role of
Arf6-regulated pathways in
microvesicle shedding from
the LOX melanoma tumor cell model
is established [16]. Comparing
highly invasive LOXARF6-GTP cells
with less invasive LOXARF6-GDP
cells revealed that LOXARF6-GDP cells
accumulated numerous vesicular
structures on the cell surface, whereas
LOXARF6-GTP cells and wild-type LOX
cells had far fewer of these structures.
Instead, LOX and LOXARF6-GTP
cells accumulated microparticles
in the culture media, and these
microparticles were much reduced in
the culture media from LOXARF6-GDP
cells. Analysis of the microparticles
purified from the culture media showed
them to have a membrane bilayer
with phosphatidylserine on the
extracellular face, and to be
heterogeneous in size, consistent
with a plasma-membrane origin
rather than a multivesicular-body
(exosome) origin. Tellingly, these
microparticles contained Arf6 protein
and cell-surface markers (b1 integrin),
as well as matrix-digesting protease
activity. This suggests that tumor
cells release matrix-digesting
microparticles to create localized
clearing of the nearby matrix
in advance of invadopodia
protrusion.
Howdoes Arf6 regulatemicroparticle
release? Unexpectedly, Arf6 does notfunction as part of a proto-vesicle coat
in microparticle formation, as might be
expected if Arf6 had an analogous
function to that of Arf1 in intracellular
vesicle formation. Instead, Arf6 acts
as a signaling intermediate to
activate a localized signaling
cascade culminating in myosin light
chain phosphorylation (Figure 1).
Determination of precisely how myosin
light chain activity leads to outward
membrane scission will require future
work. Other important outstanding
questions include whether Arf6 is
absolutely required for microparticle
formation and release (does Arf6
depletion affect this?), and what
signals upstream of Arf6 lead to
its activation on the microparticle
pathway. Clearly, the identification
of additional signaling components
and pathways that regulate this
process may identify workable
approaches to therapeutically
target early metastatic cells.
Arf6 sits in the center of a web
of interactions and signals that
affect a tumor cell’s ability to migrate
during metastasis (Figure 1), having
functions such as: directing matrix
degradation through microparticle
release [16] and through the formation
of invadosomes [7]; controlling
dynamics of cytoskeletal and focal
adhesion connections to extracellular
matrix through activation of Rac1
[2,3]; promoting general cell migration,
such as through the ArfGAPs ASAP3
[14] or GIT1/GIT2 [15]; and altering
membrane lipid composition and
producing lipid-derived messengers
[1]. One apparently critical aspect
of Arf6 function in these various
pathways is that it acts locally, so
that Arf6 activated in one location by
a particular GEF is competent to
perform certain tasks, but likely not
others [18]. This specificity suggests
that it may be possible for particular
Arf6-mediated pathways to be
targeted downstream of Arf6. With
the current work, one additional
Arf6-mediated pathway now needs
to be considered as a potential target:
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